“Long-Term Safety and Disease Control of Ruxolitinib Cream Among Adolescents With Atopic Dermatitis: Results From Two Phase 3 Studies”. SKIN The Journal of Cutaneous Medicine, vol. 6, no. 2, Mar. 2022, p. s28, https://doi.org/10.25251/skin.6.supp.28.